July 2011 July- 23 Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

Tetsuya Mitsudomi. The Lancet Oncology, Early Online Publication, 22 July 2011Tetsuya Mitsudomi. doi:10.1016/S1470-2045(11)70194-2

Clinical practice in non-small-cell lung cancer (NSCLC) has changed greatly since the introduction of EGFR tyrosine kinase inhibitors (TKIs). Subsequent discovery of activating mutations of EGFR in a subset of patients with NSCLC in 2004 opened the era of personalised therapy in thoracic oncology.

The initial findings that the EGFR mutation was associated with increased sensitivity to TKIs and was most common in the Asian population, never-smokers, women, and patients with adenocarcinoma led to the ...

Read more

Last Updated on Sunday, 24 July 2011 21:11

Hong Kong Respiratory Medicine

July 2011 July- 23 Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

July 2011 July- 23 Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

Main Menu

Administrators' Area (Requires Login)

Who's Online

Statistics since July 2009